On August 7, ZAI LAB rose 15.9% in regular trading, trading at HK$16.84/share, with turnover of HK$330 million.

The surge was driven by the company's Q2 financial results released on the evening of August 6. ZAI LAB reported total revenue of US$106.3 million for Q2, with net product revenue reaching US$105.8 million, representing an 11% sequential increase. The growth was attributed to stable performance of Zejula and continued sales momentum of Efgartigimod. Management indicated multiple pipeline catalysts are expected in the second half of the year.

The strong quarterly results come amid a series of positive developments for the company, including the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients and the European Medicines Agency orphan drug designation for Zoci in neuroendocrine carcinoma of lung origin. These approvals are expected to further expand the company's commercial portfolio and support revenue diversification going forward.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)